



RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/398,365

DATE: 09/21/99

TIME: 14:17

Input File : N:\Crif3\RULE60\09398365.RAW.txt

Output File : N:\CRF4\06022003\I398365.raw

SEQUENCE LISTING

3 (i) GENERAL INFORMATION:

4 (i) APPLICANT: Bayveland, David
 5 Baistram, John
 6 Janssen, II
 7 Anderson, Arvid J. III
 8 Markussen, Jan

11 (ii) TITLE OF INVENTION: ACTIVATED INSULIN

13 (iii) NUMBER OF SEQUENCES: 40

15 (iv) CORRESPONDENT ADDRESS:

16 (A) ADDRESSEE: Novo Nordisk of North America, Inc.
 17 18 STREET: 401 Lexington Avenue, 64th Floor
 18 (C) CITY: New York
 19 (D) STATE: New York
 20 (E) COUNTRY: United States of America
 21 (F) ZIP: 10154-6401

23 (v) COMPUTER READABLE FORM:

24 (A) MEDIUM TYPE: Floppy disk
 25 (B) COMPUTER: IBM PC compatible
 26 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 27 (D) SOFTWARE: PatentIn Release #1.0, Version #1.1

29 (vi) CURRENT APPLICATION DATA:

C--> 30 (A) APPLICATION NUMBER: US/09/398,365
 C--> 31 (B) FILING DATE: 17-Sep-1999

32 (C) CLASSIFICATION:

35 (vii) PRIOR APPLICATION DATA:

36 (A) APPLICATION NUMBER: US/08/400,256
 37 (B) FILING DATE: 03-MAR-1998

40 (viii) ATTORNEY/AGENT INFORMATION:

41 (A) NAME: Smith, Philip L.
 42 (B) REGISTRATION NUMBER: 11,111
 43 (C) FIRM/INSTITUTION: FIRM/INSTITUTION

44 (ix) CONTACT PERSON INFORMATION:

45 (A) TELEPHONE: 212-555-1212
 46 (B) TELEFAX: 212-555-1212

47 (x) INFORMATION FOR SEQ. ID NO. 1:

48 (i) SEQUENCE CHARACTERISTICS:

49 (A) LENGTH: 1000
 50 (B) TYPE: DNA

ENTERED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/398,365

DATE: 10/11/2009
TIME: 14:11

Seq. File: N:\Crif3\RULE60\09398365.RAW.txt

Seq. File: N:\CRF4\06022003\I398365.raw

```

61      1
W--> 64      Glu Asn Tyr Cys Xaa
65      10
66 (i) INFORMATION FOR SEQ ID NO: 1:
67 (i) SEQUENCE CHARACTERISTICS:
68 (A) LENGTH: 5 amino acids
69 (B) TYPE: amino acid
70 (C) STRANDEDNESS: linear
71 (D) TOPOLOGY: linear
72 (ii) MOLECULE TYPE: protein
73 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
W--> 79      Xaa Val Xaa Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
80      1          5          10          15
81      Ser Val Tyr Gly Ala Arg Gly Ile Ile Tyr Thr Pro Lys Xaa
82      20          25          30
83 (i) INFORMATION FOR SEQ ID NO: 3:
84 (i) SEQUENCE CHARACTERISTICS:
85 (A) LENGTH: 110 base pairs
86 (B) TYPE: nucleic acid
87 (C) STRANDEDNESS: single
88 (D) TOPOLOGY: linear
W--> 94      (ii) MOLECULE TYPE: DNA
89 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
90 TGCTTAAGAG AATGGTTGAC CAAGACTTAT GGTGTCTCTCA CTGGGTGAGG AGTTTGTATC
91 TGGTTGTTGG TAAAGAGAGT TTCTTCTACA CTCCAAAGTC TGACGACGCT
92 (i) INFORMATION FOR SEQ ID NO: 4:
93 (i) SEQUENCE CHARACTERISTICS:
94 (A) LENGTH: 117 base pairs
95 (B) TYPE: nucleic acid
96 (C) STRANDEDNESS: single
97 (D) TOPOLOGY: linear
W--> 111      (ii) MOLECULE TYPE: DNA
98 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
99 CTGCGGGCTG CGTCTAAGCA CAGTAGTTTT CCAATTGGTA CAAAGAACAG ATAGAAATAC
100 AAGATTGTTC AAGGATACCC TTACGGTGGT CAAATTTTGC
101 (i) INFORMATION FOR SEQ ID NO: 5:
102 (i) SEQUENCE CHARACTERISTICS:
103 (A) LENGTH: 117 base pairs
104 (B) TYPE: nucleic acid
105 (C) STRANDEDNESS: single
106 (D) TOPOLOGY: linear
W--> 128      (ii) MOLECULE TYPE: DNA
107 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
108 TCAATGATAT TAAAGATT TATTA
109 (i) INFORMATION FOR SEQ ID NO: 6:
110 (i) SEQUENCE CHARACTERISTICS:
111 (A) LENGTH: 117 base pairs
112 (B) TYPE: nucleic acid
113 (C) STRANDEDNESS: single
114 (D) TOPOLOGY: linear

```

RAW SEQUENCE LISTING

PATENT APPLICATION N: US/09/398,365

DATE: 2009-09-01
TIME: 14:11

Input File : N:\Crif3\RULE60\09398365.RAW.txt

Input File : N:\CRF4\06022003\I398365.raw

```

W--> 143      (ii) MOLECULE TYPE: DNA
145      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
147 CTGATTAAG AGATCGGCGGCG TCGGTCT
149
150 (2) INFORMATION FOR SEQ ID NO: 6:
151 (i) SEQUENCE CHARACTERISTICS:
152 (A) LENGTH: 11 base pairs
153 (B) TYPE: nucleic acid
154 (C) STRANDEDNESS: single
155 (D) TOPOLOGY: linear
156

W--> 158      (ii) MOLECULE TYPE: DNA
160      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
162 TTTTAAAGAG ATTGGTACT CAAGATTCT AGATTCTCA CTGCTTGA GATTCTACT
164 TGGTTCTTA TGAAGAGGT TTCTCTACA CTGTAAGTC TGACGACCT
166
167 (2) INFORMATION FOR SEQ ID NO: 7:
168 (i) SEQUENCE CHARACTERISTICS:
169 (A) LENGTH: 25 base pairs
170 (B) TYPE: nucleic acid
171 (C) STRANDEDNESS: single
172 (D) TOPOLOGY: linear
173

W--> 175      (ii) MOLECULE TYPE: DNA
177      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
179 GTAGCATGG CTAAGAGATT CCTTA
181
182 (2) INFORMATION FOR SEQ ID NO: 9:
183 (i) SEQUENCE CHARACTERISTICS:
184 (A) LENGTH: 100 base pairs
185 (B) TYPE: nucleic acid
186 (C) STRANDEDNESS: single
187 (D) TOPOLOGY: linear
188

W--> 190      (ii) MOLECULE TYPE: DNA
192      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
194 TTTTAAAGAG ATTGGTACT CAAGATTCT AGATTCTCA CTGCTTGA GATTCTACT
196 AAATATCTT AACGATAGC TTAGATTCA TAAAGTTG
198
199 (2) INFORMATION FOR SEQ ID NO: 10:
200 (i) SEQUENCE CHARACTERISTICS:
201 (A) LENGTH: 17 base pairs
202 (B) TYPE: nucleic acid
203 (C) STRANDEDNESS: single
204 (D) TOPOLOGY: linear
205

W--> 207      (ii) MOLECULE TYPE: DNA
209      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
211 AGTATCTT TAAAGATCG GGTCT
213
214 (2) INFORMATION FOR SEQ ID NO: 11:
215 (i) SEQUENCE CHARACTERISTICS:
216 (A) LENGTH: 9 base pairs
217 (B) TYPE: nucleic acid
218 (C) STRANDEDNESS: single
219 (D) TOPOLOGY: linear

```


RAW SEQUENCE LISTING

PATENT APPLICATION NO. US/09/398,365

1. *Pharmaceutical industry* – The pharmaceutical industry is a major source of funding for research in the field of aging. The industry has a vested interest in developing new drugs and treatments for age-related diseases.

Figure 1 is a schematic representation of the experimental design. It shows a sequence of events for two trials, Trial 1 and Trial 2. The events are: Stimulus presentation, Response, Feedback, and Inter-trial interval. The sequence is repeated for Trial 1 and Trial 2.

Input File : N:\Crf3\RULE60\09398365.RAW.txt

File Name : N:\CRF4\06022003\I398365.raw

[illegible]

415 170 INFORMATION FOR SEQ ID NO: 15:

515 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 amino acids

(13) TYPE: amino acid

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: prot. in

-72 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

324 Met Lys Ala Val Phe Ileu Val Leu Ser Leu Ile Gly Phe Cys Trp Ala

527 His Pro Val Thr Gly Asp Glu Ser Ser Val Glu His Pro Glu Glu Ser

336 Leu Ile Ile Ala Glu Asn Thr Thr Leu Ala Asn Val Ala Met Ala Lys

331 335 40 45

433 Arg Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu

534 50 51 60

436 Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ser Asp

537	65	70	75	80
-----	----	----	----	----

339 Asp Ala Lys Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu

340 85 90 95

$$\begin{array}{l}
 \text{1. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{2. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{3. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{4. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{5. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{6. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{7. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{8. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{9. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \\
 \text{10. } \frac{1}{2} \times \frac{1}{2} = \frac{1}{4}
 \end{array}$$
[illegible]

746 (2) INFORMATION FOR SEQ ID NO: 16:

348 (1) SEQUENCE CHARACTERISTICS:

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains.

(b) TFB: nucleic acid

551 (C) STRANDEDNESS: single

352 (D) TOPOLOGY: linear

W--> 354 (ii) MOLECULE TYPE: DNA

(c) *Not a member of the family*—The following are not members of the family:

*TGG CAGGCGACCA AGAAGGAGGAG C AAGTTTCAGAA CATGAATTAAG ATGCATAATT TCCGAGGAGG

[illegible]

FOR ADDITIONAL INFORMATION, SEE SPG 11, No. 17.

[illegible]

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/398,365

DATE: 09/11/2009
TIME: 14:14:14

Input File : N:\Crf3\RULE60\09398365.RAW.txt
Output File : N:\CRF4\06022003\I398365.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#1; Xaa Pos.21
Seq#1; Xaa Pos.1, 4, 30

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/398,365

DATE: 09/02/2009

TIME: 07:41:00

Input File : N:\Crif3\RULE60\09398365.RAW.txt

Output File : N:\CRF4\06022003\I398365.raw

L:1 M:246 C: Keyword misspelled or invalid format, [(P) APPLICATION NUMBER:
 L:1 M:246 C: Keyword misspelled or invalid format, [(P) FILING DATE:]
 L:64 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#1 after pos:16
 L:78 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#1 after pos:16
 M:341 Repeated in SeqNo:1
 L:84 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 2
 L:111 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 4
 L:128 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 5
 L:147 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 6
 L:158 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 7
 L:175 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 8
 L:190 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 9
 L:207 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 10
 L:222 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 11
 L:239 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 12
 L:256 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 13
 L:354 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 16
 L:479 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 19
 L:592 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 22
 L:701 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 25
 L:810 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 28
 L:919 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 31
 L:1043 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 34
 L:1156 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 37
 L:1268 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 40
 L:1409 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 43
 L:1541 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 46
 L:1651 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 49